Stockreport

Karyopharm Announces Ongoing Phase 3 SIENDO Study of XPOVIO® (Selinexor) in Patients with Endometrial Cancer Passes Planned Interim Futility Analysis: Data and Safety Monitoring Board Reco...

Karyopharm Therapeutics Inc.  (KPTI) 
Last karyopharm therapeutics inc. earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.karyopharm.com/investor-relations
PDF NEWTON, Mass., Nov. 25, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, to [Read more]